9月19日，"爱生命 更爱生活"919 尿毒症关爱日-领航会议学术计划在北京举行。会议举办了两场圆桌论坛。国内肾脏病学和血液净化领域专家齐聚一堂， 围绕"血液灌流规范化治疗对尿毒症患者的意义"与"新医保收费政策下对组合式血液净化治疗的影响"两大主题展开深入讨论，从疾病管理、技术创新、政 策支持与人文关怀等多维度，为我国尿毒症防治事业的未来发展献计献策。 随着医疗技术进步，血液净化已发展出多种模式，其中血液灌流技术作为一种重要的血液净化手段,在临床治疗中发挥着显著的作用。 防控肾病需从生活细节入手 除了医疗干预外，日常生活方式管理亦与肾脏健康息息相关。北京友谊医院刘文虎在探讨中表示，在肾脏病的防治过程中，许多日常风险因素极易被忽 视，其中患者的自我管理意识和生活方式尤为关键。刘文虎举例道，"门诊中我经常遇到这样的患者，他们虽然坚持服用降压药，却从不监测家庭血压， 错误地认为'吃药就等于治愈了'。"他分析道，诊室测量与家庭自测血压存在显著差异，患者需要主动参与健康管理，建立持续的数据反馈机制，才能真 正实现有效的慢病防控。 山西省人民医院周晓霜接着从现代生活方式的角度分析了尿毒症患者数量持续增长的原因。周晓霜表示 ...

Core Viewpoint - The recent refund announcement by Menglian County People's Hospital in Yunnan highlights the increasing scrutiny of medical institutions regarding the misuse of medical insurance funds, revealing both the hospital's proactive approach to rectify past mistakes and the underlying issues within its governance structure [2][3][4]. Group 1: Refund Announcement - Menglian County People's Hospital has initiated a refund process for patients, with amounts ranging from 0.03 yuan to 67.18 yuan, following a self-examination of its billing practices [1]. - The hospital's actions are rare in the healthcare sector, drawing significant public attention and raising questions about the integrity of medical billing practices [1]. Group 2: Background of the Incident - The refund stems from a report by the Pu'er City Medical Insurance Bureau, which identified various violations by the hospital, including excessive testing and duplicate charges, leading to a total loss of 27,883.46 yuan in medical insurance funds [2]. - The hospital has reportedly returned all misused funds and paid fines as mandated by the authorities [2]. Group 3: Regulatory Environment - The national government has intensified oversight of medical insurance fund usage, employing advanced technologies such as big data analysis and real-time monitoring to detect previously hidden violations [3]. - The proactive refund by the hospital can be seen as a response to this regulatory trend, aimed at reducing potential penalties [3]. Group 4: Governance Issues - The incident underscores significant governance failures within the hospital, as evidenced by the involvement of its leadership in serious misconduct [3]. - The hospital's focus on profit over patient care has led to a range of unethical practices, including overcharging and unnecessary medical procedures [3]. Group 5: Recommendations for Improvement - To prevent future issues, it is essential for medical institutions to establish transparent billing practices and enhance internal auditing and compliance mechanisms [4]. - The ongoing development of intelligent medical insurance supervision systems is crucial for monitoring medical practices and preventing violations [4].

今年7月25日，四川省医保局官网发文，成功侦破"5·20"特大医保诈骗案，查实成都九星肾病医院、成 都高新博力医院等5家医疗机构、相关职业骗保人存在倒卖"回流药"、免费透析等欺诈骗保行为，涉案 金额4808.47万元。截至目前，成都市医保局已全部解除5家涉案机构医保协议，公安机构刑拘35人，检 察院批准逮捕16人，移送起诉14人。 血液透析是尿毒症患者肾脏替代治疗方式之一。尿毒症患者一般需要每周2—3次定期到血液透析机构进 行血液透析。尿毒症患者一般需要长期甚至终身治疗，一般会固定在一家机构进行血液透析。为争夺患 者资源，部分血液透析机构通过免费血液透析、车接车送、包吃包住甚至发放补贴等方式拉拢尿毒症患 者。然而免费血液透析背后，部分机构被发现存在涉嫌骗保的问题。 针对血液透析领域涉嫌骗保的问题，今年4月，本报进行过报道（见《"免费"血液透析幕后》）。 据了解，针对血液透析领域及其他领域存在涉嫌骗保的问题，国家医保局发布了《关于将一次性高值医 用耗材重复使用、拉拢人员开展血液透析以及医用胶片违规收费纳入专项整治工作的通知》（以下简 称"《通知》"）。 《通知》要求，开展血液透析项目的医疗机构应当按照为患者实际 ...

Core Insights - The article discusses the development and branding strategies of Weigao Group in the medical and healthcare industry, emphasizing their commitment to quality management and innovation Group 1: Brand and Quality Management - Weigao Group has been recognized with a nomination for the China Quality Award, establishing a diversified brand system centered around "WEGO" [1] - The company implements a quality philosophy termed "10000-1=0," which signifies that even a minor defect can lead to total failure, reinforcing the importance of quality as the brand's lifeline [2] - Weigao has established a comprehensive traceability quality control system from raw material procurement to finished products, aiming for "zero defects" in product reliability [2] Group 2: Innovation and Market Leadership - Innovation is a core driver for Weigao, which holds over 2100 patents and has established 15 national and provincial innovation platforms [3] - The company has successfully broken monopolies in key areas such as medical materials and devices, transitioning from import substitution to international leadership [3] - Collaborations with institutions like the Chinese Academy of Sciences have enabled Weigao to develop domestic alternatives to imported materials, fostering a new growth dynamic in the medical device sector [3] Group 3: Cultural Integration and Brand Identity - Weigao emphasizes the integration of internal culture and external values, promoting a core value system of "conscience, sincerity, and loyalty" [4] - The company's mission is deeply embedded in its brand culture, encouraging over 30,000 employees to embody and promote the brand's values [4] - This cultural drive transforms employee pride into a pursuit of product excellence, enhancing customer trust and societal expectations of the brand [4]

Core Insights - The article discusses the significant reduction in medical service prices in China, particularly focusing on hemodialysis costs, which have dropped below 300 yuan, benefiting over one million dialysis patients [1][3][5] Group 1: Hemodialysis Price Reform - In 2024, the number of patients requiring dialysis in China is projected to reach 1.027 million, highlighting the critical need for affordable treatment options [1] - The National Healthcare Security Administration (NHSA) has issued guidelines to consolidate hemodialysis pricing, reducing the number of pricing items from 421 to 108, aiming to eliminate duplicate charges [3][8] - Provinces like Guangdong and Hunan have already implemented new pricing structures, with Guangdong setting a maximum price for hemodialysis at 390 yuan per session, while Hunan has established a base price of 330 yuan [5][7] Group 2: Broader Medical Service Price Reforms - The ongoing medical service price reform is not limited to hemodialysis but encompasses various medical services, with the NHSA aiming to standardize pricing across provinces to address historical discrepancies [8][9] - The NHSA has published 28 batches of project guidelines covering various medical fields, leading to significant price reductions in services such as ultrasound and PET/CT scans [9] - The reforms are designed to enhance transparency in medical pricing, preventing healthcare institutions from imposing additional charges under different names [7][9]

Core Viewpoint - Guangdong Province's Medical Insurance Bureau has announced the optimization and integration of medical service pricing for dialysis, ultrasound, and traditional Chinese medicine, ensuring that the financial burden on dialysis patients does not increase [1][2]. Group 1: Dialysis Service Pricing - The previous 32 items related to "machine-assisted plasma exchange" have been consolidated into 21 items under "blood dialysis fees," with a provincial maximum price set at 390 yuan per session, covering all necessary procedures and resources [2]. - The maximum price for peritoneal dialysis (manual) is set at 45 yuan per session, while automated peritoneal dialysis is priced at 16 yuan per hour [2]. - Public medical institutions must charge according to the integrated pricing for dialysis services and cannot charge separately for different components of the service [2][3]. Group 2: Traditional Chinese Medicine and Ultrasound Pricing - The previous 60 items for "ordinary acupuncture" have been consolidated into 10 pricing items for acupuncture methods, while 105 items for "fracture manual reduction" have been reduced to 9 items for orthopedic methods [4]. - The pricing for ultrasound services has been streamlined from 84 items to 13, with ultrasound report services now included in the ultrasound pricing, eliminating separate charges for reports [4]. - The maximum prices for the newly integrated services must not exceed the provincial limits, with local prices allowed to be lower [4].

中国市场充满活力——访万益特全球首席执行官陶 克瑞 "中国经济稳步增长和对医疗创新的承诺是塑造全球行业未来的重要驱动力。中国在数字医疗、扩 大优质医疗服务可及性方面所作的努力，与万益特致力于改善患者治疗效果、为专业医护人员提供支持 的目标高度契合。"在中国发展高层论坛2025年年会期间，万益特公司全球首席执行官陶克瑞在接受经 济日报记者采访时表示。 万益特是一家重要的脏器疗法公司，其产品线主要包括腹膜透析、血液透析、急重症治疗三大领 域。自1989年进入中国市场以来，万益特已经建立了涵盖研发、制造、销售及服务的完整产业链。公司 中国总部落户上海，拥有一家世界级研发中心、一家技术服务中心，并在苏州、广州、天津建立了生产 基地。 作为全球第二大医疗器械市场，中国市场充满活力，民众追求高品质医疗健康服务，对个性化和多 元化治疗方案的需求潜力巨大。陶克瑞指出，"中国在数字医疗、居家治疗和慢性病管理方面实行的利 好政策与万益特'延续生命之旅、拓展无限可能'这一使命非常契合，同时，中国在生物医学研究、人工 智能+大健康等领域的人才储备丰富，是全球重要的创新中心。万益特希望继续借助本土人才优势，持 续探索创新解决方案，助力 ...